biological therapy

Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study
Faustino Peron Filho, Andressa de Souza Moreira, Anna Larissa Faria Janes, Alexandre W S de Souza

RMD Open Mar 2024, 10 (1) e003992; DOI: 10.1136/rmdopen-2023-003992
Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System
Hugo Jourdain, Léa Hoisnard, Emilie Sbidian, Mahmoud Zureik

RMD Open Mar 2024, 10 (1) e003531; DOI: 10.1136/rmdopen-2023-003531
Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Laura C Coates, Laure Gossec, Miriam Zimmermann, May Shawi, Emmanouil Rampakakis, Natalie J Shiff, Alexa P Kollmeier, Xie L Xu, Peter Nash, Philip J Mease, Philip S Helliwell

RMD Open Mar 2024, 10 (1) e003977; DOI: 10.1136/rmdopen-2023-003977
Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project
Shikha Singla, Andre Ribeiro, Murat Torgutalp, Philip J Mease, Fabian Proft

RMD Open Jan 2024, 10 (1) e003809; DOI: 10.1136/rmdopen-2023-003809
Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort
Moritz Scheidegger, Marouane Boubaya, Alexandru Garaiman, Imon Barua, Mike Becker, Hilde Jenssen Bjørkekjær, Cosimo Bruni, Rucsandra Dobrota, Håvard Fretheim, Suzana Jordan, Oyvind Midtvedt, Carina Mihai, Anna-Maria Hoffmann-Vold, Oliver Distler, Muriel Elhai

RMD Open Jan 2024, 10 (1) e003658; DOI: 10.1136/rmdopen-2023-003658
Impact of biological therapy in reducing the risk of arthritis development in inflammatory bowel diseases
Mauro Fatica, Benedetta Monosi, Paola Conigliaro, Arianna D’Antonio, Sara Essofi, Elisa Cuccagna, Alberto Bergamini, Livia Biancone, Giovanni Monteleone, Paola Triggianese, Emma Calabrese, Maria Sole Chimenti

RMD Open Jan 2024, 10 (1) e003820; DOI: 10.1136/rmdopen-2023-003820
Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis
Philip J Mease, Soumya Reddy, Sarah Ross, Jeffrey R Lisse, Paulo Reis, Kirstin Griffing, Christophe Sapin, Aisha Vadhariya, Daniel E Furst

RMD Open Jan 2024, 10 (1) e003423; DOI: 10.1136/rmdopen-2023-003423
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Laura C Coates, Robert Landewé, Iain B McInnes, Philip J Mease, Christopher T Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D Gladman, Laure Gossec, Ana-Maria Orbai, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Joseph F Merola

RMD Open Feb 2024, 10 (1) e003855; DOI: 10.1136/rmdopen-2023-003855
Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: a nationwide cohort study from the French Health Insurance Database (SNDS)
Léa Bastard, Pascal Claudepierre, Laetitia Penso, Emilie Sbidian, Laura Pina Vegas

RMD Open Mar 2024, 10 (1) e003865; DOI: 10.1136/rmdopen-2023-003865
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS)
Laura Pina Vegas, Laetitia Penso, Emilie Sbidian, Pascal Claudepierre

RMD Open Dec 2023, 9 (4) e003570; DOI: 10.1136/rmdopen-2023-003570

Main menu

biological therapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

biological therapy

Pages